References
- Goldie JH, Coldman AJ, Grudauskas GA. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
- Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
- Norton L. The Norton-Simon hypothesis. The Chemotherapy Source Book, MC Perry. Williams & Wilkins, Baltimore 1992; 36–53
- Day R. Treatment sequencing asymmetry and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876–3885
- Gregory WH, Birkhead BG, Sonhami RC. A mathematical model of drug resistance applied to the treatment of small cell lung cancer. J Clin Oncol 1988; 6: 457–461
- Wheldon TE. Mathematical Models in Cancer Research. Adam Hilzer, Bristol 1988; 180–202
- Martin RB, Fisher HE, Minchin RF, Teo KL. A mathematical model of cancer chemotherapy with an optimal selection of parameters. Math Biosci 1990; 997: 05–230
- Ling V, Juranka KU, Endicott JA, Deuchars KL, Gerlach J. Multidrug resistance and P-glycoprotein expression. Mechanisms of Drug Resistance in Neoplastic Cells, PV Woolley, KD Tew. Academic Press, San Diego 1988; 197–211
- Pastan I, Guttesman M. Multiple drug resistance in human cancer. N Engl J Med May 28, 1987; 1388–1391
- Hamilton TC, Gi-Ming L, Rothenberg MC, Fojo A, Young RC, Ozoes RF. Mechanisms of resistance to cisplatin and alkylating agents. In: Drug Resistance in Cancer Therapy. Kluver Academic Publishers, Boston 1989; 151–170
- Martin RB, Fisher ME, Minchin RF, Teo KL. Low-intensity combination chemotherapy maximizes host survival time for tumours containing drug-resistant cells. Math Biosci 1992; 110(2)221–252
- Postmus PE, Smith EF, Kirkpatrick A, Splenter T AW. Testing the possible non-cross resistance of two equivalent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A(2)204–207
- Glick J, Tsiatis A, Schilsky R, Beck T, Oken M, Peterson B, Fisher R. for ECOG, A randomized phase III trial of MOPP/ABV hybrid vs sequential MOPP-ABVD in advanced Hodgkin's disease. Preliminary results of the intergroup trial. Proc Asco 1991; 941
- Hancock BW, Vaughn Hudson GV, Vaughn Hudson B, Bennet MH, MacLennon KA, Haybittle JL, Anderson L, Linen DC. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation Trial. J Clin Oncol 1992; 10: 7252–7258
- Fukuoka M, Furuse K, Sajo N, Nishiwaki V, Ikegami H, Tamura T, Shimoyama M, Suemasu K. A randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Nail Cancer Inst 1991; 83: 855–861
- Asselin BL. Evaluation of tumour cell heterogeneity based on response to chemotherapy. Clin Chim Acta 1992; 206: 33–44
- Cheng KC, Loeb L. Genomic instability and tumour progression: Mechanistic considerations. Adv Cancer Res 1993; 60: 121–156
- Zastawny RL, Bechimol S, Ling V. Co-promoter region of the P-glycoprotein gene insufficient to confer differential responsiveness to wild-type and mutant P-53. Oncogene 1993, in press